Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, Japan.
Dig Dis. 2012;30(6):609-16. doi: 10.1159/000343091. Epub 2012 Dec 13.
To evaluate the efficacy of sorafenib monotherapy, we enrolled 188 patients with hepatocellular carcinoma (HCC) who had undergone sorafenib monotherapy during a 3-year period from May 2009 to June 2012. Median overall survival was 15.6 months, and the 1- and 2-year survival rate was 54.4 and 32.2%, respectively, showing a relatively favorable treatment outcome. In addition, outcome was more favorable in earlier TNM stages. HCC patients with stage IVB had a better outcome than those with stage IVA, indicating the involvement of vascular invasion had poor prognosis. Outcome was more favorable in patients with Child-Pugh class A than in those with Child-Pugh class B. Patients in the long-term treatment group, who received sorafenib for ≥90 days, also showed a favorable outcome compared with those in the short-term treatment group, in which the administration period was <90 days. Multivariate analysis revealed treatment duration as a significant prognostic factor. Furthermore, patients who received post-sorafenib treatment had a better outcome than those who did not.
为了评估索拉非尼单药治疗的疗效，我们招募了 188 名肝细胞癌（HCC）患者，他们在 2009 年 5 月至 2012 年 6 月的 3 年期间接受了索拉非尼单药治疗。中位总生存期为 15.6 个月，1 年和 2 年生存率分别为 54.4%和 32.2%，显示出相对较好的治疗结果。此外，早期 TNM 分期的结果更有利。IVB 期 HCC 患者的预后优于 IVA 期患者，表明血管侵犯的参与预后不良。Child-Pugh 分级为 A 的患者的预后优于 Child-Pugh 分级为 B 的患者。接受索拉非尼治疗≥90 天的长期治疗组患者的预后也优于治疗期<90 天的短期治疗组患者。多因素分析显示治疗持续时间是一个重要的预后因素。此外，接受索拉非尼治疗后治疗的患者的预后优于未接受治疗的患者。
